Merck's PCSK9 pill clinches FDA approval Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 16 July, 2026

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

news Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley Merck beats AstraZeneca to first approval for first PCSK9 pill Exclusive: FDA acting chief walks back Makary's practice of policymaking through journals

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

ENDPOINTS PHARMA Senate committee questions CDC pick on political interference over vaccines Insilico, Bora Pharma reveal plans for AI-driven manufacturing company J&J restructures pharma manufacturing footprint at cost of up to $750M  •  J&J's 'must-win launch' Icotyde nabs 18,000 prescriptions in first full quarter Eli Lilly invests in Oura to support patients on GLP-1 drugs

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.

in case you missed it 1. Post-Hoc Live: What’s making biotech IPOs work again? •  I&I startup Attovia files to go public as biotech listings momentum builds •  Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival 2. Updated: Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger 3. Exclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney 4. Veradermics declares first efficacy win in women for hair loss drug 5. Celcuity wins approval for breast cancer drug Revtorpyk